New PET tracer could spot hidden thyroid cancer
NCT ID NCT02856347
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a special PET scan tracer called 18F-DOPA can better detect leftover medullary thyroid cancer in lymph nodes after surgery, compared to standard imaging. Twenty-four adults with elevated thyrocalcitonin levels (a sign of residual disease) received the tracer and underwent PET/CT scans. The goal was to see if this method finds more true positive nodes, which could help doctors decide on further treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-DOPA (a radioactive tracer for PET scans)
What this could lead to
If successful, this could improve detection of residual medullary thyroid cancer, guiding more precise follow-up and treatment decisions.
What could go wrong
This is a small, early-stage study (24 participants) focused on imaging accuracy, not treatment. The tracer may not prove better than existing methods, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEDULLARY THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Haut-Lévêque
Bordeaux, France
-
CHU Limoges
Limoges, France
-
CHU Timone
Marseille, France
-
ICM Montpellier
Montpellier, France
-
Institut Claudius Regaud
Toulouse, 31059, France